- Home
- ARMP vs AREC Comparison
ARMP vs AREC Comparison
Compare ARMP & AREC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- AREC
- Stock Information
- Founded
- ARMP N/A
- AREC 2013
- Country
- ARMP United States
- AREC United States
- Employees
- ARMP N/A
- AREC N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- AREC Coal Mining
- Sector
- ARMP Health Care
- AREC Energy
- Exchange
- ARMP Nasdaq
- AREC Nasdaq
- Market Cap
- ARMP 92.4M
- AREC 97.1M
- IPO Year
- ARMP N/A
- AREC 2019
- Fundamental
- Price
- ARMP $2.61
- AREC $1.78
- Analyst Decision
- ARMP Strong Buy
- AREC Strong Buy
- Analyst Count
- ARMP 1
- AREC 2
- Target Price
- ARMP $9.00
- AREC $4.00
- AVG Volume (30 Days)
- ARMP 9.3K
- AREC 3.7M
- Earning Date
- ARMP 08-12-2025
- AREC 08-19-2025
- Dividend Yield
- ARMP N/A
- AREC N/A
- EPS Growth
- ARMP N/A
- AREC N/A
- EPS
- ARMP N/A
- AREC N/A
- Revenue
- ARMP $6,868,000.00
- AREC $330,304.00
- Revenue This Year
- ARMP $8.43
- AREC $25,437.66
- Revenue Next Year
- ARMP N/A
- AREC $156.28
- P/E Ratio
- ARMP N/A
- AREC N/A
- Revenue Growth
- ARMP 84.67
- AREC N/A
- 52 Week Low
- ARMP $0.90
- AREC $0.38
- 52 Week High
- ARMP $2.96
- AREC $1.95
- Technical
- Relative Strength Index (RSI)
- ARMP 58.67
- AREC 63.67
- Support Level
- ARMP $2.43
- AREC $1.18
- Resistance Level
- ARMP $2.72
- AREC $1.53
- Average True Range (ATR)
- ARMP 0.18
- AREC 0.24
- MACD
- ARMP -0.01
- AREC -0.00
- Stochastic Oscillator
- ARMP 70.08
- AREC 79.01
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About AREC American Resources Corporation
American Resources Corp constructs and/or purchases and manages a chain of combined gasoline, diesel and natural gas (NG) fueling and service stations; construct conversion factories to convert NG to liquefied natural gas (LNG) and compressed natural gas (CNG); and construct conversion factories to retrofit vehicles currently using gasoline or diesel fuel to also run on NG in the United States and also to build a convenience store to serve its customers in each of its locations. Its segments are AIC focused on the extraction, processing, transportation, and distribution of coal for a variety of industries, with a focus on metallurgical quality coal to the steel industry; RLMT; and EMC.